$LGCXF

Lahontan Drills 31m Grading 0.90 g/t Au Oxide at Calvada Central

Lahontan Gold Corp. reported additional 2026 drill results at its Santa Fe Mine. At Calvada Central, hole CAL26-03C intersected 30.8m of 0.93 g/t Au Eq oxide, including 10.7m at 2.18 g/t Au Eq. Two RC holes at the South Slab open pit returned 15.2m at 0.40 g/t Au Eq and 9.1m at 0.22 g/t Au Eq, aimed at fault-constrained mineralization.

Original reporting
Published Jul 22, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 12:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lahontan Drills 31m Grading 0.90 g/t Au Oxide at Calvada Central — source image
Decision brief

The 30-second read

$LGCXFBullishMed
01

Why it matters

The disclosed intercepts (including a high-grade 10.7m sub-interval within CAL26-03C) are intended to strengthen confidence in the Calvada resource and mineralization continuity against the Calvada Fault.

02

Market read

Traders may reprice the probability-weighted value of the Santa Fe restart based on incremental grade and continuity evidence, ahead of later resource and PEA updates.

03

What to watch

The article provides Au Eq and oxide context but does not disclose metallurgical results, updated resource estimate timing, or whether intercepts materially expand the pit-constrained resource.

Relevance 6/10Novelty 6/10Timing: today’s drill results for the 2026 Santa Fe drilling program

Background

Lahontan is advancing the Santa Fe Mine restart in Nevada, with 2026 drilling supporting an updated MRE and PEA and mine permitting toward 2027 construction.

Company-level read

Ticker impact

$LGCXFBullishMedium confidence
Context

Lahontan reports new Santa Fe Mine drill intercepts, including 30.8m at 0.93 g/t Au Eq oxide in CAL26-03C and additional RC holes at the Slab pit.

Expected impact

Near-term upside bias for LG/OTC liquidity on drill-result momentum, with follow-through dependent on subsequent assay breadth and resource/PEA updates.

Evidence & confidence

The release is company-specific and includes multiple grade-length intercepts plus a stated link to resource confidence and mine-advancement timeline, but it is still exploration-stage and lacks updated resource/PEA numbers.

Market effects

Adds incremental positive signal for Nevada gold development sentiment, but impact is limited given the small-cap nature and absence of updated economics.

Minor read-through to Walker Lane gold exploration activity sentiment.

Low, as the disclosure is not a macro driver and does not change global gold supply-demand.

Counterpoint

High-grade intercepts may not translate into mineable ounces or economic viability without updated resource modeling, metallurgical performance, and continuity at scale.

Key entities

  • Lahontan Gold Corp.

    TSXV-listed Nevada-focused gold developer reporting additional Santa Fe Mine drill results.

  • Santa Fe Mine Project (Calvada Central, Slab open pit)

    Drilling targets where oxide gold mineralization and fault-constrained RC holes were reported.

Related articles

$CVXLow

Ministry of Petroleum and Mineral Resources and Chevron Announce Positive Results from Nargis-2 Well in the Mediterranean Sea

Chevron and Egypt's Ministry of Petroleum announced positive results from the Nargis-2 gas well in the Mediterranean. The well confirmed extended gas-bearing reservoirs and an additional gas interval, supporting further appraisal and development. Chevron operates the area with partners Eni, Mubadala Energy, and Tharwa Petroleum. The well reached 5,000 meters with 35 meters of net gas pay, indicating potential for further development.

$GMABMed

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab and Incyte are collaborating on clinical trials for metastatic colorectal cancer. The trials will evaluate the combination of Genmab's petosemtamab and Incyte's INCB161734 with standard chemotherapy. Petosemtamab targets EGFR and LGR5, while INCB161734 inhibits KRAS G12D. The companies aim to provide a new treatment option for patients with KRAS G12D-mutated metastatic colorectal cancer.

$INCYMedAI 8/10

Incyte and Genmab Announce Clinical Trial Collaboration in Metas

Incyte (INCY) and Genmab (GMAB) are collaborating on a clinical trial to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's bispecific antibody petosemtamab and standard chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The Phase 1/2 study will be co-funded by both companies, with Genmab conducting the trial and Incyte providing the clinical supply of INCB161734. This collaboration aims to address a significant unmet medical need in this patient population.